RESUMEN
Purpose: Patients with cirrhosis from genotype 3 (GT3) hepatitis C virus (HCV) infection are difficult to cure. This study investigated the effectiveness and safety of sofosbuvir-velpatasvir (SOF/VEL) with and without ribavirin (RBV) in patients with GT3 HCV-infection-related cirrhosis from Xinjiang, China. Patients and Methods: This study included 33 patients with GT3 HCV infected cirrhosis, who were treated with either SOF/VEL+RBV for 12 weeks (n = 27) or SOF/VEL alone for 24 weeks (n = 6) between January 2019 and June 2021. The primary endpoint was a sustained virological response at 12 weeks (SVR12), post-treatment. Secondary endpoints included changes from baseline in Child-Pugh-Turcotte scores, clinical results, hepatic-encephalopathy status, ascites, and gastrointestinal bleeding at 12 weeks, post-treatment. Results: Out of the 33 patients, 18 (54.6%) were diagnosed with GT3a, 15 (45.4%) with GT3b, 16 (48.5%) with compensated cirrhosis, and 17 (51.5%) with decompensated cirrhosis. SVR12 was 87.9% (compensated cirrhosis: 93.8%, decompensated cirrhosis: 82.4%). The Child-Pugh-Turcotte scores improved at 12 weeks (p < 0.05). Total bilirubin, albumin, and alanine transaminase levels, as well as hepatic-encephalopathy were significantly improved among patients with compensated and decompensated cirrhosis (p < 0.05). The blood cell count and serum creatinine levels did not deteriorate. Conclusion: SOF/VEL, with and without RBV, was effective, safe, and well-tolerated as a treatment for GT3 HCV associated cirrhosis.
RESUMEN
BACKGROUND: The aim of this study was to explore the correlation of gene polymorphisms of human leukocyte antigen-DQB1 (HLA-DQB1) with the infection outcome and replication status of hepatitis B virus (HBV) positive patients in the Xinjiang Uygur population in China. METHODS: 110 cases of chronic hepatitis B (CHB) of Xinjiang Uygur were examined clinically, which were named as the CHB group; 100 cases carrying chronic HBV (ASC) served as ASC group; 80 cases of self-limited HBV infection (RHBS) were recorded as RHBS group. Genotypes of HLA-DQB1 were detected by sequence specific primer-polymerase chain reaction (PCR-SSP) method, and the differences of gene frequency among groups were also compared. The distribution frequencies of the HLA-DQB1 gene under different replication states of HBV were compared. RESULTS: The distribution frequency of DQB1*0201 in the RHBS group was higher than that of the ASC group (18.75%, 10.50%, χ(2) = 5.959, P < 0.05, OR = 2.257). The distribution frequency of DQB1*0201 in the CHB group was higher than that of the ASC group (17.73%, 10.50%, χ(2) = 5.363, P < 0.05, OR = 2.066). The distribution frequency of DQB1*0301 in the CHB group was higher than that of the ASC group (26.82%, 16.50%, χ(2) = 9.062, P < 0.05, OR = 2.349). The distribution frequency of DQB1*0303 in the CHB group was lower than that of the ASC group (19.55%, 31.00%, χ(2) = 10.996, P < 0.05, OR = 0.393). There was no statistically significant difference in the allele frequencies among all other groups. The distribution frequency of DQB1*0201 in the low replication group was higher than that of the high replication group (17.08%, 10.56%, χ(2) = 4.295, P < 0.05, OR = 1.939). CONCLUSION: HLA-DQB1*0201 is a HBV resistance gene in Xinjiang Uygur. DQB1*0301 is correlated with continuous infection of HBV. DQB1*0303 is a susceptibility gene of ASC.
